Wealthfront Advisers LLC Raises Stock Holdings in Stryker Corporation $SYK

Wealthfront Advisers LLC grew its position in Stryker Corporation (NYSE:SYK) by 27.8% in the 1st quarter, Holdings Channel.com reports. The fund owned 50,755 shares of the medical technology company’s stock after acquiring an additional 11,046 shares during the quarter. Wealthfront Advisers LLC’s holdings in Stryker were worth $16,678,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also modified their holdings of the company. Brighton Jones LLC raised its position in Stryker by 15.4% in the 4th quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock valued at $1,643,000 after purchasing an additional 609 shares during the last quarter. Schnieders Capital Management LLC. purchased a new position in Stryker during the 2nd quarter worth $205,000. Marshall Wace LLP increased its stake in Stryker by 107.9% in the second quarter. Marshall Wace LLP now owns 5,700 shares of the medical technology company’s stock valued at $2,255,000 after purchasing an additional 77,831 shares during the period. Nebula Research & Development LLC acquired a new position in Stryker in the second quarter valued at $219,000. Finally, HUB Investment Partners LLC purchased a new stake in shares of Stryker in the second quarter valued at about $253,000. 77.09% of the stock is owned by institutional investors and hedge funds.

Stryker Trading Up 4.5%

Shares of Stryker stock opened at $330.64 on Friday. Stryker Corporation has a 52-week low of $281.00 and a 52-week high of $404.87. The company has a quick ratio of 1.25, a current ratio of 2.11 and a debt-to-equity ratio of 0.62. The company’s 50-day simple moving average is $312.00 and its 200-day simple moving average is $336.94. The firm has a market cap of $126.76 billion, a price-to-earnings ratio of 38.27, a price-to-earnings-growth ratio of 2.03 and a beta of 0.77.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). Stryker had a net margin of 13.20% and a return on equity of 23.42%. The firm had revenue of $6.02 billion during the quarter, compared to analyst estimates of $6.34 billion. During the same quarter in the previous year, the business earned $2.84 EPS. Stryker’s revenue for the quarter was up 2.6% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, equities research analysts anticipate that Stryker Corporation will post 14.98 earnings per share for the current year.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date of this dividend is Tuesday, June 30th. Stryker’s dividend payout ratio is currently 40.74%.

Insiders Place Their Bets

In other news, VP M Kathryn Fink sold 5,220 shares of the company’s stock in a transaction on Monday, May 11th. The shares were sold at an average price of $283.85, for a total transaction of $1,481,697.00. Following the transaction, the vice president directly owned 13,137 shares of the company’s stock, valued at $3,728,937.45. This represents a 28.44% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Robert S. Fletcher sold 4,544 shares of the stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the completion of the transaction, the vice president owned 10,582 shares of the company’s stock, valued at $3,247,298.34. This represents a 30.04% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 323,264 shares of company stock worth $100,659,489. 4.60% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the stock. Wells Fargo & Company decreased their target price on shares of Stryker from $456.00 to $418.00 and set an “overweight” rating for the company in a research note on Friday, May 1st. Argus set a $370.00 price target on Stryker in a research report on Thursday, July 9th. BTIG Research set a $371.00 price objective on Stryker in a research note on Monday. Sanford C. Bernstein set a $410.00 price objective on Stryker in a research report on Friday, May 1st. Finally, JPMorgan Chase & Co. lowered their target price on Stryker from $445.00 to $400.00 and set an “overweight” rating on the stock in a research note on Friday, May 1st. One investment analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat, Stryker presently has a consensus rating of “Moderate Buy” and an average target price of $392.52.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.